Ovarian Carcinoma — Trials

Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

895 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 270
Recruiting: 140
Ph III recruiting: 16
Growth YoY: +23.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (145)

clinicaltrialsPublishedShowing 101–107 of 107 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03907527	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	active not recruiting	Phase 1	71	Precigen, IncINDUSTRY	1	Nov 8, 2024	clinicaltrials
NCT05620134	Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer	active not recruiting	Phase 1 / Phase 2	263	Salubris Biotherapeutics IncINDUSTRY	2	Oct 15, 2024